What is the recommended bicalutamide dose, duration, and monitoring for short‑course androgen deprivation therapy in prostate cancer patients undergoing radiation?

Bicalutamide Dosing, Duration, and Monitoring for Short-Course ADT with Radiation in Prostate Cancer

For short-course androgen deprivation therapy combined with radiotherapy in prostate cancer, bicalutamide 150 mg daily for 6 months is the recommended dose and duration, with baseline and periodic liver function monitoring required.

Dose and Duration

Standard Short-Course Regimen

• Bicalutamide 150 mg once daily orally for 6 months is the established dose when used as short-course ADT with radiotherapy 1.
• This dose is distinct from the FDA-approved 50 mg dose used in combination with LHRH analogs for metastatic disease 2.
• The 6-month duration aligns with evidence showing that short-course ADT (4-6 months) combined with radiotherapy improves disease control in intermediate-risk and locally advanced prostate cancer 3.

Risk-Stratified Duration Considerations

• Intermediate-risk disease: 6 months of ADT with radiotherapy (if radiation dose <70 Gy) provides significant benefit 3.
• High-risk/locally advanced disease (≥T2b): While 6 months is the minimum effective duration, 24 months of ADT is superior to short-course therapy for high-risk patients, reducing the risk of metastasis and improving overall survival 3.
• A recent meta-analysis confirms optimal ADT duration is approximately 9-12 months for most patients, with diminishing relative benefits beyond this point 4.

Evidence from Key Trials

• The RTOG 96-01 trial specifically evaluated bicalutamide 150 mg daily for 24 months during and after salvage radiotherapy, demonstrating improved freedom from PSA progression (57% vs 40%) and reduced metastasis incidence (7.4% vs 12.6%) 3.
• The RADICALS-HD trial showed that 24 months of ADT (including bicalutamide options) significantly improved 10-year metastasis-free survival compared to 6 months (78.1% vs 71.9%) in the postoperative radiotherapy setting 5.

Monitoring Requirements

Hepatic Monitoring (Critical)

• Baseline liver function tests (serum transaminases) are mandatory before initiating bicalutamide 2.
• Monitor liver enzymes at regular intervals during the first 4 months of treatment, then periodically thereafter 2.
• Severe hepatic injury and fatal hepatic failure have been reported; use with caution in patients with hepatic impairment 2.
• Discontinue bicalutamide if patients develop jaundice or clinical evidence of hepatic dysfunction 2.

Cardiovascular Monitoring (Especially Important)

• Baseline cardiac assessment is essential in patients with pre-existing cardiovascular disease before starting bicalutamide, particularly when combined with LHRH agonists 6.
• In men with a history of coronary artery disease, heart failure, or prior myocardial infarction, bicalutamide combined with LHRH therapy was associated with increased all-cause mortality (adjusted HR 1.96) 6.
• Consider cardiology referral for risk stratification when combining bicalutamide with LHRH agonists in patients with cardiac comorbidities 6.
• The combination of bicalutamide plus LHRH agonist more than doubled the odds of severe cardiac or neurologic events (OR 2.48) in RTOG 9601 6.

PSA Monitoring

• Regular PSA monitoring is recommended to assess treatment response and detect disease progression 2.
• Evaluate for clinical progression if PSA increases during or after treatment 2.

Glucose Monitoring

• When bicalutamide is used with LHRH agonists, monitor blood glucose as LHRH agonists reduce glucose tolerance in males 2.

Anticoagulation Monitoring

• If patients are receiving coumarin anticoagulants, closely monitor PT/INR and adjust anticoagulant doses as needed, as bicalutamide may affect coagulation parameters 2.

Important Clinical Considerations

Gynecomastia Prevention

• Prophylactic breast bud irradiation (single 8 Gy fraction) within the first month of starting long-term bicalutamide (>6 months) significantly reduces painful gynecomastia 1, 7.
• Gynecomastia (68.8%) and breast pain (73.7%) are the most common adverse events with bicalutamide 150 mg 8.

When Bicalutamide is Preferred Over LHRH Agonists

• Bicalutamide 150 mg is an alternative to LHRH agonist therapy in men who place high value on retaining sexual function during treatment 1.
• In patients with pre-existing cardiovascular morbidity, bicalutamide may be preferred over long-term LHRH analogs due to lower cardiovascular risk with monotherapy 3.
• However, the cardiovascular safety advantage is lost when bicalutamide is combined with LHRH agonists 6.

Contraindications and Cautions

• Bicalutamide is contraindicated in women and pregnancy 2.
• Males with female partners of reproductive potential should use effective contraception during treatment and for 130 days after the final dose 2.
• The 150 mg dose is not approved for use alone or with other treatments in the United States for early prostate cancer 2.

Common Pitfalls to Avoid

• Do not use the 50 mg dose for monotherapy or short-course ADT with radiation; this dose is only approved for combination with LHRH analogs in metastatic disease 2.
• Do not assume bicalutamide monotherapy equals LHRH analog efficacy for high-risk disease; there is no direct evidence that antiandrogen monotherapy provides the same overall survival benefit as long-term LHRH analogs 3.
• Do not overlook cardiovascular risk assessment before combining bicalutamide with LHRH therapy, especially in patients with cardiac history 6.
• Do not extend ADT beyond 24-36 months without clear indication, as there is no evidence of additional benefit and cardiovascular risks increase with duration 3, 6.